-
Jci Nanjing University Chen Xi/Yan Chao/Yin Rong discovered that the cancer-causing KRAS signaling pathway evades innate immune surveillance of lung adenocarcinoma by activating CD47
Time of Update: 2023-01-01
On November 22, 2022, Chen Xi, Yan Chao and Yin Rong of Nanjing University jointly published a report entitled "Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung" online in the Journal of Clinical Investigation (IF=19).
-
Issue 44/2014 - New renewable polypropylene is approved for food contact in the United States
Time of Update: 2022-11-13
(Xiaohua) Recently, KW Plastics Co.
(Xiaohua) Recently, KW Plastics Co.
(Xiaohua) Recently, KW Plastics Co.
This means that this 100% renewable polypropylene plastic can be used safely in food packaging production.
This means that this 100% renewable polypropylene plastic can be used safely in food packaging production.
-
The legendary creature CAR-T sells well in Europe and the United States! Domestic CAR-T is still involutional! "Going to sea" through the winter
Time of Update: 2022-11-05
October 2017 Targeting CD19October 2017The FDA approved Gilead's Yescarta for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) who have previously received second- or multi-line systemic therapy.
-
Upstart BTK inhibitor sells at least $11 billion globally in 2021
Time of Update: 2022-05-28
Globally Approved BTK Inhibitors(Source: CITIC Securities Research)Sales of major BTK inhibitors have continued to grow since their launch .
(Data source: annual reports of each company, tirabrutinib sales in 2021 are the data from listing to March 2021)At present, many domestic pharmaceutical companies are also deploying BTK inhibitors .
-
Yifan Pharmaceutical: FDA will delay approval of F-627 marketing application
Time of Update: 2022-04-19
This time, the controlled subsidiary received a notification from the FDA that the FDA was unable to conduct on-site inspections of the subsidiary's production due to travel restrictions and delayed the approval of the F-627 listing application.
-
The label restrictions are settled
Time of Update: 2021-12-27
Just a few days ago, the FDA updated the labels of these drugs, requiring patients to use TNF inhibitors before using newer JAK inhibitors for approved indications, such as rheumatoid arthritis .
-
Domestically-made innovative drugs are speeding up overseas, and many new drugs are about to be launched abroad
Time of Update: 2021-10-22
S. Food and Drug Administration (FDA) has also accepted Baiyueze® for the treatment of marginal zone lymphoma (MZL) adults who have previously received at least one CD20-directed therapy The patient’s New Indication Marketing Application (sNDA) and granted priority review qualifications .
-
The first generic carfilzomib for injection of Hausen Pharmaceuticals was approved for only two months after the original research report
Time of Update: 2021-09-11
From: CDE official websiteCarfilzomib (carfilzomib) is a proteasome inhibitor, approved by the FDA on July 20, 2012, for patients with multiple myeloma who have received at least two previous types (bortezomib and immunomodulators).
-
With PI3Kα/δ dual inhibitor, CP Tianqing won its first breakthrough therapy
Time of Update: 2021-08-10
In terms of solid tumors, Tianqing also initiated a phase 1b clinical trial in combination with fulvestrant in the treatment of HR-positive and HER2-negative PIK3CA-mutated advanced breast cancer, and another for PI3KA mutation or PTEN deletion/low expression advanced bone tumors.
-
FDA agrees to Phase III pivotal clinical trial of procrulamide for the treatment of hospitalized male and female patients with new crown
Time of Update: 2021-07-06
At the same time, the FDA agreed to expand the inclusion of female patients in the phase III pivotal clinical trial of Prokalamide for mild and moderate new crowns .
-
Lay off 186 people
Time of Update: 2021-07-06
On Tuesday, a Novartis spokesperson said that Novartis will transfer the previously shared Aimovig's joint business operations in the United States to Amgen, including but not limited to sales, marketing and medical support functions .
-
The world's first: CStone Pharmaceuticals announces that the Phase III registration clinical trial of sugarizumab for the treatment of non-small cell lung cancer has reached the primary endpoint
Time of Update: 2021-07-06
" CStone Pharmaceuticals plans to submit a new drug application (NDA) for sugarizumab to the China National Medical Products Administration for the treatment of phase III NSCLC indications in the near future, and will work closely with EQRx, including the U.
-
Innovative JAK inhibitor phase III clinical results achieved breakthrough results, significantly improved psoriasis symptoms and good safety
Time of Update: 2021-07-01
On April 24, 2021, Bristol-Myers Squibb (BMS) announced the positive results of its potential "first-in-class" oral selective TYK2 inhibitor deucravacitinib in the treatment of patients with moderate to severe psoriasis Phase III clinical trials .
-
The long-acting GLP-1 hypoglycemic drug "Semaglutide Injection" is about to be approved
Time of Update: 2021-05-09
From: NMPA; the review time axis is attached at the end of the articleSemaglutide injection (Semaglutide, English trade name: Ozempic) is a long-acting GLP-1 receptor agonist developed by Novo Nordisk.
-
Drug-resistant tuberculosis treatment ushered in a new breakthrough, the course of treatment or shortened by one-third
Time of Update: 2021-03-20
In a new study in 2019, the UCLA David Geffen School of Medicine team reported that the treatment of drug-resistant tuberculosis can be greatly reduced by using a method called "artificial intelligence-parabolic response surface" time.
